"We are pleased the FDA has accepted our NDA for Bumetanide Nasal Spray," said Benjamin Esque, CEO of Corstasis Therapeutics ...

The NDA is supported by data from a clinical trial that compared the absorption and efficacy of the nasal treatment with oral and IV bumetanide in 68 healthy adults.

9NEWS Medical Expert Dr. Payal Kohli weighs in on a new nasal spray being used to treat depression. 14 Outdated Home Trends That Are Lowering Your Property Value ...

PDUFA date of March 27, 2025 for CARDAMYST™ (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT)- Commercial capabilities ...

Spravato, a newly FDA-approved nasal spray, offers hope for individuals with treatment-resistant depression, a condition ...

The results? A nasal spray of oxytocin significantly reduced acute feelings of loneliness in participants, especially during group therapy sessions, even months after treatment. In the study ...

Now, the Food and Drug Administration (FDA) has expanded approval for Johnson & Johnson's nasal spray, Spravato, to be used as a standalone treatment for people with severe depression who haven't ...

PDUFA date of March 27, 2025 for CARDAMYST (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT) - Commercial capabilities build out in process, with proposed launch in PSVT targe ...

A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US. The FDA first approved the Johnson & Johnson drug, called ...

Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Milestone Pharmaceuticals (MIST – Research Report) and keeping the ...

A one-time nasal spray has been approved by the Food and Drug Administration as a standalone treatment for depression. The drug made by Johnson & Johnson under the brand name Spravato passed final ...

Johnson & Johnson's nasal spray received US FDA approval The nasal spray is used for the treatment of major depressive disorder The drug brought in sales of $780 million in 2024 The US Food and Drug ...